会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明申请
    • ANIONIC POLYAMIDE FUNCTIONALIZED BY A TRYPTOPHAN UNIT
    • 由TRYPTOPHAN UNIT功能化的阴离子聚酰胺
    • WO2009144577A2
    • 2009-12-03
    • PCT/IB2009005798
    • 2009-06-01
    • ADOCIASOULA REMI
    • SOULA REMI
    • C08G69/10A61K38/00A61K47/34A61K47/48A61P43/00C08G69/08C08G69/48C08G73/10
    • C08G69/48A61K47/645C08G69/10
    • The invention relates to an anionic polyamide functionalized by at least one tryptophan unit, -Trp, said tryptophan unit being bonded to the polyamide by an amide function separated from the backbone by a linker arm L, the polyamide being a chain selected from the group consisting of the following polymers: Formulas (I), (II), (III), L being selected from the group consisting of a simple link, a -CH2- group, or a -CH2CH2- group, -Trp being a tryptophan residue, L and/or D, produced by the coupling of the amino of the tryptophan or a tryptophan derivative, selected from the group consisting of tryptophanol, tryptophanamide, and the alkaline cation salts thereof, and an acid carried by the polyamide. The present invention also relates to a pharmaceutical composition containing one of the polyamides according to the invention.
    • 本发明涉及由至少一个色氨酸单元-Trp功能化的阴离子聚酰胺,所述色氨酸单元通过由主链与连接臂L分离的酰胺官能团键合到聚酰胺上,所述聚酰胺是选自以下的链: 的以下聚合物:式(I),(II),(III),L选自简单连接基团,-CH 2 - 基团或-CH 2 CH 2 - 基团,-Trp是色氨酸残基, 通过色氨酸的氨基或选自色氨酸,色氨酰胺及其碱性阳离子盐的色氨酸衍生物的偶联产生的L和/或D和由聚酰胺携带的酸。 本发明还涉及含有本发明的聚酰胺之一的药物组合物。
    • 5. 发明申请
    • ANGIOGENIC COMPOSITION
    • 生物成分
    • WO2008120085A3
    • 2009-09-11
    • PCT/IB2008000762
    • 2008-03-31
    • ADOCIASOULA OLIVIERSOULA GERARDSOULA REMIELOY ROSY
    • SOULA OLIVIERSOULA GERARDSOULA REMIELOY ROSY
    • A61K47/48A61K9/00A61K38/18A61P9/10
    • A61K9/0014A61K38/1858A61K47/61
    • The invention relates to the use of an amphiphilic polymer for the preparation of a therapeutic composition that is intended to promote angiogenesis at the administration site thereof, comprising a complex between a polymer and a platelet-derived growth factors (PDGF), characterised in that the polymer is amphiphilic. In one embodiment of the invention, the PDGF is selected from the PDGF group and the amphiphilic polymer is selected from the group comprising amphiphilic polymers formed by a hydrophilic polymer backbone functionalised with hydrophobic substituents and hydrophilic groups having general formula (I). The invention also relates to the use of same in accordance with these claims, characterised in that the therapeutic composition takes the form of a gel, cream, solution, spray, paste, patch or bandage.
    • 本发明涉及两亲性聚合物在制备治疗组合物中的用途,所述治疗组合物旨在促进其施用部位的血管发生,其包含聚合物与血小板衍生生长因子(PDGF)之间的复合物,其特征在于, 聚合物是两亲性的。 在本发明的一个实施方案中,PDGF选自PDGF基团,两亲性聚合物选自由疏水取代基官能化的亲水性聚合物骨架和具有通式(I)的亲水基团形成的两亲聚合物。 本发明还涉及根据权利要求的用途,其特征在于治疗组合物采取凝胶,霜剂,溶液,喷雾剂,糊剂,贴剂或绷带的形式。
    • 6. 发明申请
    • POLYGLUTAMIC ACIDS FUNCTIONALISED BY HISTIDINE DERIVATIVES AND HYDROPHOBIC GROUPS AND THE USES THEREOF IN PARTICULAR FOR THERAPEUTIC PURPOSES
    • 西地丁衍生物和疏水基团作用的多聚谷氨酸及其用途,特别是用于治疗目的的用途
    • WO2007051923A3
    • 2007-06-28
    • PCT/FR2006002443
    • 2006-10-31
    • FLAMEL TECH SASOULA OLIVIERSOULA REMIBREYNE OLIVIER
    • SOULA OLIVIERSOULA REMIBREYNE OLIVIER
    • C07K2/00A61K47/48C08G69/10
    • C08G69/10A61K8/88A61K2800/57A61Q19/00C07K14/001
    • The invention relates to novel biodegradable materials based on modified polyomino acids and suitable, in particular, for vectoring active substance(s) (AS). Said invention also relates to novel pharmaceutical, cosmetic, dietary or plant protective compositions which are based on said polyamino acids. The aim of said invention is to provide a novel polymer raw material usable for vectoring the AS and capable to optimally meet all specification in this area: biocompatibility, biodegradability, ability to become easily associated with many active substances or to solubilise them and to release said active substances in vivo. The aim is attained by the invention which relates to novel polyglutomates modified by histidine derivatives and hydrophobic groups containing from 8 to 30 carbon atoms. Said polyglutomates modified by histidine derivatives are soluble with pH lower than 5 and are easily and economically convertible into active substance vectorisation particles which are able to form stable aqueous colloidal suspensions. On the contrary, said modified polyglutamates are insoluble in water with a physiological pH (7, 4), and thereby have to be precipitated on an injection site in the case of a subcutaneous injection.
    • 本发明涉及基于改性的多酚酸的新型生物可降解材料,并且特别适用于载体活​​性物质(AS)。 本发明还涉及基于所述聚氨基酸的新型药物,化妆品,膳食或植物保护组合物。 本发明的目的是提供一种新型聚合物原料,其可用于载体AS并能最佳地满足该领域的所有规格:生物相容性,生物降解性,易与许多活性物质结合或溶解它们并释放所述物质 体内活性物质。 本发明通过涉及由组氨酸衍生物和含有8至30个碳原子的疏水基团修饰的新型多聚谷氨酸盐的发明达到目的。 所述由组氨酸衍生物修饰的多聚谷氨酸盐在pH低于5时是可溶的,并且容易且经济地转化为能够形成稳定的含水胶态悬浮液的活性物质载体化颗粒。 相反,所述改性聚谷氨酸盐不溶于具有生理pH(7,4)的水中,因此在皮下注射的情况下必须在注射部位沉淀。